Literature DB >> 12482085

Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

K Herholz1, E Salmon, D Perani, J C Baron, V Holthoff, L Frölich, P Schönknecht, K Ito, R Mielke, E Kalbe, G Zündorf, X Delbeuck, O Pelati, D Anchisi, F Fazio, N Kerrouche, B Desgranges, F Eustache, B Beuthien-Baumann, C Menzel, J Schröder, T Kato, Y Arahata, M Henze, W D Heiss.   

Abstract

A new diagnostic indicator of FDG PET scan abnormality, based on age-adjusted t statistics and an automated voxel-based procedure, is presented and validated in a large data set comprising 110 normal controls and 395 patients with probable Alzheimer's disease (AD) that were studied in eight participating centers. The effect of differences in spatial resolution of PET scanners was minimized effectively by filtering and masking. In controls FDG uptake declined significantly with age in anterior cingulate and frontolateral perisylvian cortex. In patients with probable AD decline of FDG uptake in posterior cingulate, temporoparietal, and prefrontal association cortex was related to dementia severity. These effects were clearly distinct from age effects in controls, suggesting that the disease process of AD is not related to normal aging. Women with probable AD had significantly more frontal metabolic impairment than men. The new indicator of metabolic abnormality in AD-related regions provided 93% sensitivity and specificity for distinction of mild to moderate probable AD from normals, and 84% sensitivity at 93% specificity for detection of very mild probable AD (defined by Mini Mental Score 24 or better). All regions related to AD severity were already affected in very mild AD, suggesting that all vulnerable areas are affected to a similar degree already at disease onset. Ventromedial frontal cortex was also abnormal. In conclusion, automated analysis of multicenter FDG PET is feasible, provides insights into AD pathophysiology, and can be used potentially as a sensitive biomarker for early AD diagnosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12482085     DOI: 10.1006/nimg.2002.1208

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  255 in total

1.  Cerebral Blood Flow Is Associated with Diagnostic Class and Cognitive Decline in Alzheimer's Disease.

Authors:  Wenna Duan; Parshant Sehrawat; Arvind Balachandrasekaran; Ashish B Bhumkar; Paresh B Boraste; James T Becker; Lewis H Kuller; Oscar L Lopez; H Michael Gach; Weiying Dai
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

Review 2.  The concept of FDG-PET endophenotype in Alzheimer's disease.

Authors:  Emmanuel H During; R S Osorio; F M Elahi; L Mosconi; M J de Leon
Journal:  Neurol Sci       Date:  2011-06-01       Impact factor: 3.307

3.  Characterizing Alzheimer's disease using a hypometabolic convergence index.

Authors:  Kewei Chen; Napatkamon Ayutyanont; Jessica B S Langbaum; Adam S Fleisher; Cole Reschke; Wendy Lee; Xiaofen Liu; Dan Bandy; Gene E Alexander; Paul M Thompson; Leslie Shaw; John Q Trojanowski; Clifford R Jack; Susan M Landau; Norman L Foster; Danielle J Harvey; Michael W Weiner; Robert A Koeppe; William J Jagust; Eric M Reiman
Journal:  Neuroimage       Date:  2011-01-27       Impact factor: 6.556

4.  Cerebral blood flow by arterial spin labeling in poststroke dementia.

Authors:  M J Firbank; J He; A M Blamire; B Singh; P Danson; R N Kalaria; J T O'Brien
Journal:  Neurology       Date:  2011-04-26       Impact factor: 9.910

5.  [Functional magnetic resonance imaging and dementia].

Authors:  F L Giesel; A Hempel; P Schönknecht; T Wüstenberg; M A Weber; J Schröder; M Essig
Journal:  Radiologe       Date:  2003-06-24       Impact factor: 0.635

6.  Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies?

Authors:  Mateen C Moghbel; Babak Saboury; Sandip Basu; Scott D Metzler; Drew A Torigian; Bengt Långström; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02       Impact factor: 9.236

Review 7.  Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Authors:  Lisa Mosconi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-04       Impact factor: 9.236

Review 8.  Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging.

Authors:  Valentina Berti; Lisa Mosconi; Alberto Pupi
Journal:  PET Clin       Date:  2014-04

Review 9.  Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease.

Authors:  Lisa Mosconi; Alberto Pupi; Mony J De Leon
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

10.  Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.

Authors:  Sylvia E Perez; Bin He; Muhammad Nadeem; Joanne Wuu; Stephen W Scheff; Eric E Abrahamson; Milos D Ikonomovic; Elliott J Mufson
Journal:  Biol Psychiatry       Date:  2014-01-11       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.